Lexicon Pharmaceuticals (LXRX) Retained Earnings (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Retained Earnings data on file, last reported at $2.2 billion in Q1 2026.

• On a quarterly basis, Retained Earnings rose 4.89% year-over-year to $2.2 billion in Q1 2026; TTM through Mar 2026 was $2.2 billion, a 4.89% increase from a year earlier, with the FY2025 full-year figure at $30000.0, up 100.0% from the prior year.
• Retained Earnings for Q1 2026 stood at $2.2 billion, up from $30000.0 in the prior quarter.
• Over the last five years, Retained Earnings for LXRX reached as high as $2.2 billion in Q1 2026 and fell as low as -$2.0 billion in Q4 2024.
• Historically, Retained Earnings has averaged $336.7 million across 5 years, with a median of $30000.0 in 2025.
• On a YoY basis, Retained Earnings climbed as much as 17091540.0% in 2022 and fell as far as 30716680.0% in 2022.
• Year by year, Retained Earnings stood at $1.7 billion in 2022, then advanced by 8.98% to $1.9 billion in 2023, then sank by 205.62% to -$2.0 billion in 2024, then surged by 100.0% to $30000.0 in 2025, then soared by 7413316.67% to $2.2 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $2.2 billion in Q1 2026, $30000.0 in Q4 2025, and $2.1 billion in Q3 2025.